{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06016179",
            "orgStudyIdInfo": {
                "id": "2023-137"
            },
            "organization": {
                "fullName": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",
                "class": "OTHER"
            },
            "briefTitle": "Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer",
            "officialTitle": "Phase I Intra-patient Dose Escalation Study of the IL-6 Receptor Antagonist Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Pleural Effusion or Peritoneal Ascites Due to Metastatic Cancer",
            "acronym": "RIOT2",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "tocilizumab-delivered-via-pleural-and-peritoneal-catheters-in-patients-with-advanced-metastatic-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-28",
            "studyFirstSubmitQcDate": "2023-08-23",
            "studyFirstPostDateStruct": {
                "date": "2023-08-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Patrick Wagner, MD, FACS",
                "investigatorTitle": "Investigator",
                "investigatorAffiliation": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)"
            },
            "leadSponsor": {
                "name": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.",
            "detailedDescription": "This is an open label, Phase 1, intra-patient dose escalation study to determine the feasibility of catheter-based intra-pleural and intra-peritoneal administration of tocilizumab at doses up to 50\u03bcg/mL in patients with malignant pleural effusions (MPE) and malignant ascites (MA) and to determine the frequency and type of adverse events.\n\nTocilizumab is a monoclonal antibody inhibitor of the IL-6 receptor, FDA-approved for intravenous administration in autoimmune disorders and cytokine release syndrome. The current study aims to adapt this agent for intra-cavitary administration in patients\n\nA drain catheter will be placed in the patient as standard of care treatment. Following the procedure, on that day and once a week for the following 3 weeks, tocilizumab will be administered to the patient via the drain. Each treatment session will last about one hour, and participants donate 6 milliliters (1 teaspoon) of blood before and after the treatment. Fluid drained from the body cavity, which is normally discarded, will instead be collected for analysis."
        },
        "conditionsModule": {
            "conditions": [
                "Malignant Pleural Effusion",
                "Malignant Ascites"
            ],
            "keywords": [
                "Malignant Pleural Effusion",
                "Malignant Ascites",
                "Tocilizumab",
                "IL-6 receptor antagonist",
                "peritoneal cavity",
                "pleural cavity",
                "intraperitoneal",
                "intrapleural"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Intra-patient dose escalation administration of tocilizumab via pleural and peritoneal catheters",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment Arm - intracavitary tocilizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5\u03bcg/mL and increasing to 1.6\u03bcg/mL, 5\u03bcg/mL and 50\u03bcg/mL once a week over four weeks.",
                    "interventionNames": [
                        "Drug: Tocilizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tocilizumab",
                    "description": "Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5\u03bcg/mL and increasing to 1.6\u03bcg/mL, 5\u03bcg/mL and 50\u03bcg/mL once a week over four weeks.",
                    "armGroupLabels": [
                        "Treatment Arm - intracavitary tocilizumab"
                    ],
                    "otherNames": [
                        "Actemra"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Successful intra-cavitary administration of tocilizumab",
                    "description": "Number of patients with successful administration of tocilizumab",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Adverse Events",
                    "description": "To identify the frequency and type of adverse events (AE) following intrapleural or intraperitoneal administration of tocilizumab at doses up to 2.5 mg (intrapleural) or 25 mg (intraperitoneal) using CTCAE v5.0",
                    "timeFrame": "6 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics Analysis",
                    "description": "Measuring serum receptor occupancy levels",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Pharmacokinetics Analysis",
                    "description": "Measuring intracavity fluid receptor occupancy levels",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Biomarkers",
                    "description": "Change in Pleural cytokine concentrations",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Biomarkers",
                    "description": "Change in Peritoneal Cytokine concentrations",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Biomarkers",
                    "description": "Change in immune cell density",
                    "timeFrame": "4 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects age 18-89 years old with pleural effusion or peritoneal ascites due to metastatic cancer\n2. Scheduled to undergo standard-of-care placement of pleural or peritoneal drainage catheter\n3. ECOG performance status: 0-2\n4. Able to read and sign consent form in English and provide informed consent\n\nExclusion Criteria:\n\n1. Laboratory abnormalities that indicate clinically significant inflammatory process AST/SGOT \\> 2 times the upper limit of normal ALT/SGPT \\> 2 times the upper limit of normal Total bilirubin \\> 2 times the upper limit of normal Creatinine \\> 2 times the upper limit of normal Hemoglobin \\< 8gm/dL White blood cell count \\< 3,000/ mm3 Platelet count \\< 70,000/mm3 Absolute neutrophil cell count \\< 2,000 per mm3\n2. Subjects who are unable to comply with study procedures including travel for weekly outpatient clinic visits\n3. Pregnant women\n4. Active immunotherapy within 30 days; concurrent chemotherapy or targeted therapy is permitted but for patients with a history of prior immunotherapy, the most recent dose should be \\>30 days prior to the first treatment visit\n5. Investigational drug use within 30 days prior to first treatment dose\n6. History of systemic autoimmune disease\n7. Patient with known hypersensitivity to tocilizumab\n8. Active infection\n9. Medical contraindication or history of adverse reaction to acetaminophen or diphenhydramine\n\n   -",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "89 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Patrick Wagner, MD",
                    "role": "CONTACT",
                    "phone": "412-359-3731",
                    "email": "patrick.wagner@ahn.org"
                },
                {
                    "name": "AHN Clinical Trial Contact",
                    "role": "CONTACT",
                    "phone": "412-330-6151",
                    "email": "clinicaltrials@ahn.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Patrick Wagner, MD",
                    "affiliation": "Director of Complex General Surgical Oncology",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Allegheny Health Network Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Patrick Wagner, MD",
                            "role": "CONTACT",
                            "phone": "412-359-3731",
                            "email": "patrick.wagner@ahn.org"
                        },
                        {
                            "name": "AHN Clinical Trials Contact",
                            "role": "CONTACT",
                            "phone": "412-330-6011",
                            "email": "clinicaltrials@ahn.org"
                        },
                        {
                            "name": "Patrick Wagner, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Ghosh Sohini, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Catherine Lewis, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Stephanie Baltaji, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                },
                {
                    "id": "D000016066",
                    "term": "Pleural Effusion, Malignant"
                },
                {
                    "id": "D000010996",
                    "term": "Pleural Effusion"
                },
                {
                    "id": "D000001201",
                    "term": "Ascites"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000010995",
                    "term": "Pleural Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000010997",
                    "term": "Pleural Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13886",
                    "name": "Pleural Effusion",
                    "asFound": "Pleural Effusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18563",
                    "name": "Pleural Effusion, Malignant",
                    "asFound": "Malignant Pleural Effusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4509",
                    "name": "Ascites",
                    "asFound": "Ascites",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                },
                {
                    "id": "M13885",
                    "name": "Pleural Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13887",
                    "name": "Pleural Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                }
            ]
        }
    },
    "hasResults": false
}